| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 21.05.
| Cellectis introduces human iPS derived hepatocyte product | | - | Pharma Bus Review |
| 21.05.
| Cellectis stem cells today proudly announces the launch of the world's very first human iPS cell-derived hepatocyte product | | 82 | Business Wire |
| Regulatory News:
Cellectis stem cells, a Business Unit of
Cellectis Group
(Alternext: ALCLS), a premier provider of stem cell derived products and
...
Mehr lesen zu:
Cellectis stem cells today proudly announces the launch of the world's very first human iPS cell-derived hepatocyte product | |
| 25.04.
| Precision BioSciences Files Tenth Patent Infringement Lawsuit Against Cellectis Related to Meganuclease Technology and Requests Permanent Injunction | | 64 | MarketWire |
| RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 04/25/12 -- Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a patent infringement lawsuit...
Mehr lesen zu:
Precision BioSciences Files Tenth Patent Infringement Lawsuit Against Cellectis Related to Meganuclease Technology and Requests Permanent Injunction | |
| 04.04.
| Precision BioSciences Files Ninth Patent Infringement Lawsuit Against Cellectis Related to Engineered Meganucleases | | 63 | MarketWire |
| RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 04/04/12 -- Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a patent infringement lawsuit against...
Mehr lesen zu:
Precision BioSciences Files Ninth Patent Infringement Lawsuit Against Cellectis Related to Engineered Meganucleases | |
| 02.04.
| Appointment of Mathieu Simon, MD, to the Position of Senior Vice-President of Cellectis Group | | 30 | Business Wire |
| Regulatory News:
Cellectis (Paris: ALCLS), the French specialist in genome engineering
has announced the appointment of Dr Mathieu Simon to the position of...
Mehr lesen zu:
Appointment of Mathieu Simon, MD, to the Position of Senior Vice-President of Cellectis Group | |
| 27.03.
| Precision BioSciences Files Seventh and Eighth Patent Infringement Lawsuits Against Cellectis, Seeks Permanent Injunction and Monetary Damages | | 47 | MarketWire |
| RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 03/27/12 -- Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed two additional patent infringement...
Mehr lesen zu:
Precision BioSciences Files Seventh and Eighth Patent Infringement Lawsuits Against Cellectis, Seeks Permanent Injunction and Monetary Damages | |
| 13.03.
| Precision BioSciences Announces Sixth Patent Infringement Lawsuit Against Cellectis, Seeks Permanent Injunction Against Importation Into U.S. | | 55 | MarketWire |
| RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 03/13/12 -- Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a sixth patent infringement lawsuit...
Mehr lesen zu:
Precision BioSciences Announces Sixth Patent Infringement Lawsuit Against Cellectis, Seeks Permanent Injunction Against Importation Into U.S. | |
| 06.03.
| Precision BioSciences Files Fifth Patent Infringement Lawsuit against Cellectis Related to Engineered Meganucleases | | 54 | Business Wire |
| Precision BioSciences, Inc., a leader in the field of genome
engineering, today announced that it has filed a fifth patent
infringement lawsuit against Cellectis SA and...
Mehr lesen zu:
Precision BioSciences Files Fifth Patent Infringement Lawsuit against Cellectis Related to Engineered Meganucleases | |
| 21.02.
| Precision BioSciences Files Two New Infringement Lawsuits against Cellectis, Requests Permanent Injunction against Importation of Infringing Materials into U.S. | | 51 | Business Wire |
| Precision BioSciences, Inc., a leader in the field of genome
engineering, today announced that it has filed two patent infringement
lawsuits against Cellectis SA and a...
Mehr lesen zu:
Precision BioSciences Files Two New Infringement Lawsuits against Cellectis, Requests Permanent Injunction against Importation of Infringing Materials into U.S. | |
| 13.02.
| Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million | | 47 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS) (Alternext: ALCLS), the French genome
engineering specialist, is announcing the redemption of all the bonds
...
Mehr lesen zu:
Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million | |
| 31.01.
| Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet | | 69 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering
company and subsidiary of Cellectis (Alternext: ALCLS), announces today...
Mehr lesen zu:
Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet | |
| 30.01.
| Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences | | 47 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS)(Alternext: ALCLS), the French genome
engineering specialist, is announcing the operational withdrawal of
...
Mehr lesen zu:
Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences | |
| 23.01.
| Precision BioSciences Announces that the US Patent Office Rejects All Claims to Cellectis Patent | | 40 | Business Wire |
| Precision BioSciences, Inc., a leader in the field of genome
engineering, today announced that the United States Patent and Trademark
Office (PTO) has issued a first,...
Mehr lesen zu:
Precision BioSciences Announces that the US Patent Office Rejects All Claims to Cellectis Patent | |
| 16.01.
| Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | | 23 | PR Newswire |
| QUEBEC CITY, QC and SAINT PAUL, MN, Jan. 16, 2012 /PRNewswire/ - Medicago Inc.
(MDG: TSX), a biotechnology company focused on developing highly
effective and competitive vaccines based on proprietary...
Mehr lesen zu:
Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | |
| 16.01.
| Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | | 39 | Business Wire |
| Regulatory News:
Medicago Inc. (TSX: MDG), a biotechnology company focused on
developing highly effective and competitive vaccines based on
proprietary...
Mehr lesen zu:
Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | |
| 09.01.
| Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products | | 43 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS), the French genome engineering specialist, is
today announcing that it has signed an agreement with Total to develop...
Mehr lesen zu:
Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products | |
| 03.01.
| Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership | | 70 | Business Wire |
| Regulatory News:
Cellectis plant sciences, the plant genome engineering company and
subsidiary of Cellectis (Paris:ALCLS), today announced that it has
...
Mehr lesen zu:
Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership | |
| 08.12.
| Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines | | 69 | Business Wire |
| Regulatory News:
Cellectis bioresearch, the specialist in genome customization and
commercial subsidiary of Cellectis (Paris:ALCLS), and Syngene
International...
Mehr lesen zu:
Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines | |
| 05.12.
| Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company | | 25 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS), the genome engineering specialist (Alternext:
ALCLS), is announcing that it has signed a license agreement with
...
Mehr lesen zu:
Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company | |
